[1] | R. Krishna Chandran, N. Geetha, K. M. Sakthivel, R. Suresh Kumar, K. M. N. Jagathnath Krishna, and Н. Sreedharan, “Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia”, Front. Oncol., 2019 Mar 5, V. 9, pp. 88, doi: 10.3389/fonc.2019.00088. |
[2] | K. Morales-Chacón, C. Bourlon, A. A. Acosta-Medina, M. T. Bourlon, A. Aguayo, and E. Tuna-Aguilar, “Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population”, Clin. Lymphoma Myeloma Leuk., 2019 Jun., 19(6), e299-e306, doi: 10.1016/j.clml.2019.02.007. |
[3] | International Standing Committee on Human Cytogenomic Nomenclature, ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020), Ed. J. McGowan-Jordan, R. J. Hastings, and S. Moore, Karger, 2020, 170 p. |
[4] | T. S. Wan, “Cancer Cytogenetics: An Introduction”, Methods Mol. Biol., 2017, 1541, pp. 1-10. doi: 10.1007/978-1-4939-6703-2_1. |
[5] | T. J. McKee and S. V. Komarova, “Is it time to reinvent basic cell culture medium?”, Am. J. Physiol. Cell Physiol, 2017 May 1, 312(5), pp. 624-C626, doi: 10.1152/ajpcell.00336.2016. |
[6] | T. Yao and Y Asayama. “Animal-cell culture media: History, characteristics, and current issues”, Reprod. Med. Biol., 2017 Mar 21, 16(2), pp. 99-117, doi: 10.1002/rmb2.12024. |
[7] | T. Ackermann and S Tardito, “Cell Culture Medium Formulation and Its Implications in Cancer Metabolism”, Trends Cancer, 2019 Jun, 5(6), pp. 329-332, doi: 10.1016/j.trecan.2019.05.004. |
[8] | H Zhang, K Yarinome, R Kawakami, K Otomo, T Nemoto, and Y. Okamura, “Nanosheet wrapping-assisted coverslip-free imaging for looking deeper into a tissue at high resolution”, PLoS. One., 2020 Jan 10, 15(1), e0227650, doi: 10.1371/journal.pone.0227650. |
[9] | K. A. Rack, E. van den Berg, C. Haferlach, H. B. Beverloo, D. Costa, B. Espinet, N. Foot, S. Jeffries, K. Martin, S. O'Connor, J. Schoumans, P. Talley, N. Telford, S. Stioui, Z. Zemanova, and R. J. Hastings, “European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms”, Leukemia, 2019, 33, pp. 1851-1867, doi: 10.1038/s41375-019-0378-z. |
[10] | A. Hochhaus, M. Baccarani, R. T. Silver, C. Schiffer, J. F. Apperley, F. Cervantes, R. E. Clark, J. E. Cortes, M. W. Deininger, F. Guilhot, H. Hjorth-Hansen, T.P. Hughes, J. J. W. M. Janssen, H. M. Kantarjian, D. W. Kim, R. A. Larson, J. H. Lipton, F. X. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, J. P. Radich, D. Rea, J. Richter, G. Rosti, P. Rousselot, G. Saglio, S. Saußele, S. Soverini, J.L. Steegmann, A. Turkina, A. Zaritskey, and R. Hehlmann, “European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia”, Leukemia, 2020 Apr, 34(4), pp. 966-984, doi: 10.1038/s41375-020-0776-2. |
[11] | I. Sadovnik, H. Herrmann, G. Eisenwort, K. Blatt, G. Hoermann, N. Mueller, W.R. Sperr, and P. Valent, “Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications”, Exp. Hematol., 2017 Jul, 51, pp. 17-24. doi: 10.1016/j.exphem.2017.04.003. |
[12] | B. Xu, S. Wang, R. Li, K. Chen, L. He, M. Deng, V. Kannappan, J. Zha, H. Dong, and W. Wang, “Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2”, Cell Death Dis., 2017, 8 (5), e2797, doi: 10.1038/cddis.2017.176. |
[13] | K. Blatt, I. Menzl, G. Eisenwort, S. Cerny-Reiterer, H. Herrmann, S. Herndlhofer, G. Stefanzl, I. Sadovnik, D. Berger, A. Keller, A. Hauswirth, G. Hoermann, M. Willmann, T. Rülicke, H. Sill, W.R. Sperr, C. Mannhalter, J.V. Melo, U. Jäger, V. Sexl, and P. Valent, “Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia”, Neoplasia, 2018 Jun, 20 (6), pp. 632-642. doi: 10.1016/j.neo.2018.04.004. |
[14] | M. Houshmand, A. Kazemi, A. Anjam Najmedini, M.S. Ali, V. Gaidano, A. Cignetti, C. Fava, D. Cilloni, G. Saglio, and P. Circosta, “Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells”, J. Clin. Med., 2021 Dec 11, 10 (24), pp. 5805, doi: 10.3390/jcm10245805. |
[15] | Y. Chen, J. Zou, F. Cheng, and W. Li, “Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells”, Front. Oncol., 2021 Oct 28, 11, pp. 769730. doi: 10.3389/fonc.2021.769730. |
[16] | WHO Classification of Tumours of the Hematopoietic and Lymphoid tissues, Lyon: IARC, 2017, 585 p. |
[17] | K. Allen-Proctor, E. Ruckdeschel, and R. Naous, “A novel three-way Philadelphia Variant t(9;22;17)(q34;q11.2;q12) in chronic myeloid leukemia: A case report”, Mol. Clin. Oncol., 2018 Feb, 8 (2), pp. 300-301, doi: 10.3892/mco.2017.1529. |
[18] | Q. Li, X. J. Lin, H. Chen, J. Gong, Z. Li, and X. N. Chen, “Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia. Oncol Lett. 2018 Apr; 15(4): 4599-4603. doi: 10.3892/ol.2018.7866. |
[19] | M. Asif, A. Hussain, A. Wali, N. Ahmed, I. Ali, Z. Iqbal, M. Amir, M. Shafiq, and M. Rasool, “Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations”. Anal. Cell Pathol. (Amst), 2021 Aug 12, 2021, pp. 4909012, doi: 10.1155/2021/4909012. |
[20] | A. Iglesias, R. Oancea, C. Cotarelo, and E. Anguita, “Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review”, Biomed. Rep., 2021 Oct, 15 (4), pp. 83, doi: 10.3892/br.2021.1459. |
[21] | M. Molica, F. Massaro, and M. Breccia, “Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update”, Expert Rev. Mol. Diagn., 2017 Nov, 17 (11), pp. 1001-1008, doi: 10.1080/14737159.2017.1383156. |
[22] | E. Dander, C. Palmi, G. D'Amico, and G. Cazzaniga, “The Bone Marrow Niche in B-Cell Acute Lymphoblastic Leukemia: The Role of Microenvironment from Pre-Leukemia to Overt Leukemia”, Int. J. Mol. Sci., 2021 Apr 23, 22 (9), pp. 4426. doi: 10.3390/ijms22094426. |
[23] | M. Bocchia, A. Sicuranza, E. Abruzzese, A. Iurlo, S. Sirianni, A. Gozzini, S. Galimberti, L. Aprile, B. Martino, P. Pregno, F. Sorà, G. Alunni, C. Fava, F. Castagnetti, L. Puccetti, M. Breccia, D. Cattaneo, M. Defina, O. Mulas, C. Baratè, G. Caocci, S. Sica, A. Gozzetti, L. Luciano, M. Crugnola, M. Annunziata, M. Tiribelli, P. Pacelli, I. Ferrigno, E. Usala, N. Sgherza, G. Rosti, A. Bosi, and D. Raspadori, “Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission”, Front Oncol., 2018, 8, pp. 194, doi: 10.3389/fonc.2018.00194. |
[24] | I. Aguiñiga-Sánchez, J. Cadena-Íñiguez, E. Santiago-Osorio, G. Gómez-García, V. M. Mendoza-Núñez, J. Rosado-Pérez, M. Ruíz-Ramos, V. M. Cisneros-Solano, E. Ledesma-Martínez, A. J. Delgado-Bordonave, and R. M. Soto-Hernández, “Chemical analyses and in vitro and in vivo toxicity of fruit methanol extract of Sechium edule var. nigrum spinosum”, Pharm Biol., 2017 Dec, 55 (1), pp. 1638-1645, doi: 10.1080/13880209.2017.1316746. |
[25] | S. Oney-Birol, “Exogenous L-Carnitine Promotes Plant Growth and Cell Division by Mitigating Genotoxic Damage of Salt Stress”, Sci Rep., 2019 Nov 21, 9 (1), pp. 17229, doi: 10.1038/s41598-019-53542-2. |